Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder

Addiction

Volumn 109, Issue 9, 2014, Pages 1489-1500

  Ling, Walter ^a   Chang, Linda ^b   Hillhouse, Maureen ^a   Ang, Alfonso ^a   Striebel, Joan ^a   Jenkins, Jessica ^a   Hernandez, Jasmin ^a   Olaer, Mary ^a   Mooney, Larissa ^a   Reed, Susan ^a   Fukaya, Erin ^b   Kogachi, Shannon ^b   Alicata, Daniel ^b   Holmes, Nataliya ^b   Esagoff, Asher ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c FRIENDS RESEARCH INSTITUTE   (United States)

Author keywords

Methamphetamine; Methamphetamine use disorders; Methylphenidate; Randomized clinical trial; RCT; Treatment

Indexed keywords

CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION; METHYLPHENIDATE;

ADULT; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG THERAPY; FEMALE; FOLLOW UP; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HAWAII; HUMANS; LOS ANGELES; MALE; METHYLPHENIDATE; TREATMENT OUTCOME;

EID: 84927695039     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12608     Document Type: Article

References (55)

1. United Nations Office on Drugs and Crime. World Drug Report. 2013. Available at: http://www.unodc.org/unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf (accessed 6 September 2013).
2. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication no. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
3. Elkashef A., Vocci F., Hanson G., White J., Wickes W., Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Subst Abuse 2008; 29: 31-49.
4. Elkashef A. M., Rawson R. A., Anderson A. L., Li S. H., Holmes T., Smith E. V. etal. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008; 33: 1162-1170.
5. Newton T. F., Roache J. D., De L., Garza II, R., Fong T., Wallace C. L. etal. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006; 31: 1537-1544.
6. Shoptaw S., Heinzerling K. G., Rotheram-Fuller E., Steward T., Wang J., Swanson A. N. etal. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008; 96: 222-232.
7. Batki S. L., Moon J., Delucchi K., Bradley M., Hersh D., Smolar S. etal. Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann NY Acad Sci 2000; 909: 260-263.
8. Colfax G. N., Santos G. M., Das M., Santos D. M., Matheson T., Gasper J. etal. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry 2011; 68: 1168-1175.
9. Piasecki M. P., Steinagel G. M., Thienhaus O. J., Kohlenberg B. S. An exploratory study: the use of paroxetine for methamphetamine craving. J Psychoact Drugs 2002; 34: 301-304.
10. Shoptaw S., Huber A., Peck J., Yang X., Liu J., Dang J. etal. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 12-18.
11. Anderson A. L., Li S. H., Biswas K., McSherry F., Holmes T., Iturriaga E. etal. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012; 120: 135-141.
12. Brodie J. D., Figueroa E., Laska E. M., Dewey S. L. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005; 55: 122-125.
13. Coffin P. O., Santos G. M., Das M., Santos D. M., Huffaker S., Matheson T. etal. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction 2013; 108: 751-761.
14. Elkashef A., Kahn R., Yu E., Iturriaga E., Li S. H., Anderson A. etal. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction 2012; 107: 1297-1306.
15. Galloway G. P., Buscemi R., Coyle J. R., Flower K., Siegrist J. D., Fiske L. A. etal. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther 2011; 89: 276-282.
16. Grant J. E., Odlaug B. L., Kim S. W. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol 2010; 20: 823-828.
17. Heinzerling K. G., Shoptaw S., Peck J. A., Yang X., Liu J., Roll J. etal. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 177-184.
18. Johnson B. A., Ait-Daoud N., Elkashef A. M., Smith E. V., Kahn R., Vocci F. etal., the Methamphetamine Study Group. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol 2008; 11: 1-14.
19. Ling W., Shoptaw S., Hillhouse M., Bholat M. A., Charuvastra C., Heinzerling K. etal. Double-blind placebo-controlled evaluation of the Prometa protocol for methamphetamine dependence. Addiction 2012; 107: 361-369.
20. Meredith C. W., Jaffe C., Yanasak E., Cherrier M., Saxon A. J. An open-label pilot study of risperidone in the treatment of methamphetamine dependence. J Psychoact Drugs 2007; 39: 167-172.
21. Meredith C. W., Jaffe C., Cherrier M., Robinson J. P., Malte C. A., Yanasak E. V. etal. Open trial of injectable risperidone for methamphetamine dependence. J Addict Med 2009; 3: 55-65.
22. Urschel H. C. 3rd, Hanselka L. L., Baron M. A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. J Psychopharmacol 2011; 25: 254-262.
23. Zorick T., Sevak R. J., Miotto K., Shoptaw S., Swanson A. N., Clement C. etal. Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence. J Exp Pharmacol 2009; 2010: 13-18.
24. Tiihonen J., Kuoppasalmi K., Föhr J., Tuomola P., Kuikanmäki O., Vorma H. etal. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007; 164: 160-162.
25. Aron A. R., Dowson J., Sahakian B. J., Robbins T. W. Methylphenidate improves response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2003; 54: 1465-1468.
26. Biederman J., Spencer T. Methylphenidate in treatment of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002; 6: S101-107.
27. Faraone S. V. Etiology and path physiology of adult attention-deficit/hyperactivity disorder. Prim Psychiatry 2004; 11: 28-40.
28. Faraone S. V., Spencer T., Aleardi M., Pagano C., Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol 2004; 54: 24-29.
29. Wilens T., Pelham W., Stein M., Conners C. K., Abikoff H., Atkins M. etal. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003; 42: 424-433.
30. Seeman P., Madras B. K. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998; 3: 386-396.
31. Dougherty D. D., Bonab A. A., Spencer T. J., Rauch S. L., Madras B. K., Fischman A. J. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354: 2132-2133.
32. Collins S. L., Levin F. R., Foltin R. W., Kleber H. D., Evans S. M. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend 2006; 82: 158-167.
33. Herin D. V., Rush C. R., Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann NY Acad Sci 2010; 1187: 76-100.
34. Spencer T. J., Adler L. A., McGough J. J., Muniz R., Jiang H., Pestreich L. Efficacy and safety of capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61: 1380-1387.
35. Martin W. R., Sloan J. W., Sapira J. D., Jasinski D. R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12: 245-258.
36. Sandoval V., Riddle E., Hanson G., Fleckstein A. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther 2003; 304: 1181-1187.
37. Volkow N. D., Wang G. J., Fowler J. S. etal. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am J Psychiatry 1997; 154: 50-55.
38. Volkow N. D., Wang G. J., Fowler J. S. etal. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 2002; 46: 79-82.
39. Hanson G. R., Sandoval V., Riddle E., Fleckenstein A. E. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Ann NY Acad Sci 2004; 1025: 146-150.
40. Levin F. R., Evans S. M., Brooks D. J., Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87: 20-29.
41. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G. etal. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
42. Childress A. R., McLellan A. T., O'Brien C. P. Conditioned responses in a methadone population: a comparison of laboratory, clinic, and natural settings. J Subst Abuse Treat 1986; 3: 173-179.
43. Kaplan R. F., Cooney N. L., Baker L. H., Gillespie R. A., Meyer R. E., Pomerlau O. F. Reactivity to alcohol-related cues: physiological and subjective responses in alcoholics and non-problem drinkers. J Stud Alcohol 1985; 46: 267-272.
44. Tiffany S. T., Singleton E., Haertzen C. A., Henningfield J. E. The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993; 34: 19-28.
45. Connors C. K., Erhardt D., Epstein J. N., Parker J. D. A., Sitarenios G., Sparrow E. Self-ratings of ADHD symptoms in adults I: factor structure and normative data. J Atten Disord 1999; 3: 141-151.
46. Lavori P. W. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology 1992; 6: 39-48.
47. Diggle P. J., Liang K. Y., Zeger S. L. Analysis of Longitudinal Data. New York: Oxford University Press, Inc.; 1994.
48. Littell R. C., Milliken G. A., Stroup W. W., Wolfinger R. D. SAS System for Mixed Models. Cary, NC, USA: SAS Institute, Inc.; 1996.
49. Breslow N. E., Clayton D. G. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993; 88: 9-25.
50. SAS Institute. MIXED; PROC MIXED; GLMM: CLIMMIX macro. Cary, NC: SAS Institute, Inc.; 1996.
51. Diggle P. J. Testing for random dropouts in repeated measure data. Biometrics 1989; 45: 1255-1258.
52. Ling W., Shoptaw S., Rawson R. A., Klett C. J. A composite score for evaluating treatment response in cocaine pharmacotherapy trials (TES). In: Harris L. S., editor. Problems of Drug Dependence, 1994: Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc., vol. II. National Institute on Drug Abuse Research Monograph 153. NIH Pub. no. (ADM) 95-3883. Washington, DC: Superintendant of Documents, US Government Printing Office; 1995, p. 495.
53. McCann D., Li S. A novel nonbinary evaluation of success and failure reveals B=bupropion efficacy versus methamphetamine dependence: re-analysis of a multisite trial. CNS Neurosci Ther 2012; 18: 414-418.
54. Miles S. W., Sheridan J., Russell B., Kydd R., Wheeler A., Walters C. etal. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction 2013; 108: 1279-1286.
55. Fergusson D. M., Boden J. M. Cannabis use and adult ADHD symptoms. Drug Alcohol Depend 2008; 95: 90-96.